How Retatrutide Was Administered in the Clinical Trials

Route and frequency in the published trials

The answer is the same in all seven registered trials with published designs: a subcutaneous injection, once a week. The ClinicalTrials.gov entries for both phase 2 studies describe every retatrutide arm in the same words, "administered as SC injection once weekly (QW)", and the TRIUMPH design paper describes "weekly subcutaneous retatrutide compared to placebo" across all four phase 3 trials.

The 2022 phase 1b paper explains the interval: retatrutide's pharmacokinetics were dose proportional with a half-life of approximately 6 days, which the authors judged "suitable for once-weekly dosing".

Nothing else has been tested in people. There is no oral retatrutide, no daily regimen and no twice-weekly split in the published literature. A search of the trial registry for LY3437943 returns subcutaneous once-weekly studies only. A description of any other regimen is a description of something with no human data behind it.

Escalation under protocol

The second constant is the ladder. Except for the fixed 0.5 mg and 1 mg arms, no participant received their maintenance dose on day one. In the NEJM obesity trial the 12 mg group went 2, 4, 8 then 12 mg, with escalation completed by week 12 according to the registry; the 8 mg groups went either 2, 4, 8 or 4, 8; the 4 mg groups either 2 then 4 or straight to 4.

The Lancet diabetes trial mirrored the design. The phase 3 TRIUMPH trials use a fixed 16-week escalation to 4, 9 or 12 mg, then 64 weeks of maintenance. In each case the steps were set by the protocol and applied to every participant in the arm; they were not adjusted to the individual.

The reason is written into the NEJM results: gastrointestinal adverse events were dose-related and "partially mitigated with a lower starting dose (2 mg vs. 4 mg)". In the diabetes trial, the 8 mg fast-escalation group (4 then 8 mg) reported mild-to-moderate gastrointestinal events in 50% of participants against 35% across all retatrutide groups.

The details of that comparison, and the finding that final weight loss did not depend on the starting dose, are in the titration guide; the week-by-week layout is in the dosing schedule guide.

What the protocols leave open

It is worth separating what the papers specify from what readers assume they specify. The abstracts and the design paper fix the route, the interval, the dose levels, the escalation length and the duration. They do not print an injection site, a time of day, a day of the week, or a rule about meals.

Absorption from subcutaneous tissue is slow, meals are irrelevant to an injected peptide, and with a 6-day half-life the hour of an injection changes exposure by a negligible amount, so the omission is not surprising. This site records the omission rather than filling it: no site, time or meal rule appears here because none appears in the sources.

The registry entry for the obesity trial adds one detail about the product itself: escalation was achieved "by increasing the volume of administered study drug (or placebo)", which means participants received a fixed-concentration solution prepared by the sponsor, with the injected volume set to deliver the assigned mass. The study drug was therefore a pharmaceutical product with release testing, not a research vial reconstituted on site.

Dose reductions in the protocols

The TRIUMPH design paper is the most explicit published source on what the protocol did when an assigned dose did not suit a participant. A permanent dose reduction is permitted "for management of gastrointestinal adverse events or inadequate oral intake that has not improved with other mitigations, including a prior de-escalation and re-escalation attempt".

Separately, a reduction is allowed for anyone whose BMI reaches 22 kg/m2 or lower, or who perceives excessive weight loss. The protocol treats the assigned dose as a ceiling, not a target that must be held.

On interruptions of dosing the published material is silent, and this site does not invent a rule. On stopping, the trials include a 4-week safety follow-up after the last dose and, in TRIUMPH-1, a 24-week extension for a subset that continues on drug; no off-treatment weight data for retatrutide has been published, a gap discussed in the trial duration guide. The pharmacokinetics behind the weekly interval are in the half-life guide.

Diet, activity and other drugs in the trials

Retatrutide was never tested as "drug only". The TRIUMPH paper describes retatrutide "in conjunction with healthy diet and physical activity", and states that all participants receive individual lifestyle counselling. The phase 2 diabetes trial enrolled people on diet and exercise alone or on a stable dose of metformin of at least 1,000 mg a day, and TRANSCEND-T2D-1 enrolled people on diet and exercise alone. The weight and HbA1c figures on this site therefore describe retatrutide plus counselling, against placebo plus the same counselling.

Two exclusions are informative. The phase 2 obesity trial excluded people with diabetes, and the diabetes trials used dulaglutide 1.5 mg as a separate active-comparator arm rather than combining drugs. No published trial has combined retatrutide with another incretin agonist, so no dose for such a combination exists in the literature.

The parameters, for the record

Condensed, the administration parameters of the published trials are: once-weekly subcutaneous exposure; a fixed-concentration sponsor-prepared solution whose injected volume was increased to escalate the dose; maintenance doses of 0.5 to 12 mg across the adult trials, with 4, 9 and 12 mg in phase 3; and 12 mg as the ceiling of the human data.

Those are the parameters a laboratory study citing the clinical program would reference, with any species or model adjustments belonging to that study. The full dose table is on the retatrutide dosage guide, and the concentration arithmetic for research vials is in the reconstitution guide.

Adverse events by dose, including the heart-rate increase that peaked at 24 weeks in the NEJM trial, are covered on the sister site https://retatrutiderisk.com, in particular its heart-rate article.

Back to the retatrutide dosage guide